Pfützner Andreas, Wilhelm Birgit, Forst Thomas
IKFE - Institute for Clinical Research and Development, Mainz, Germany.
Vasc Health Risk Manag. 2007;3(2):211-20. doi: 10.2147/vhrm.2007.3.2.211.
Type 2 diabetes has become a major burden to the health care systems worldwide. Among the drugs approved for this indication, glimepiride and rosiglitazone have gained substantial importance in routine use. While glimepiride stimulates beta-cell secretion and leads to reduction of blood glucose values, rosiglitazone activates PPARgamma and improves insulin resistance, at the vascular and metabolically active cells. Therefore, the combination of the two drugs may be an interesting approach to improve glycemic control and lower cardiovascular risk. A fixed combination of both drugs has been approved for clinical use in the US and EU. The combination of glimepiride and rosiglitazone is generally well tolerated and the use of a fixed combination may lead to improved adherence of the patients to their therapy. The purpose of this review is to evaluate the clinical data that have been published on this combination, appearing to represent a convenient way to obtain therapeutic targets in patients with type 2 diabetes mellitus.
2型糖尿病已成为全球医疗保健系统的一项重大负担。在获批用于该适应症的药物中，格列美脲和罗格列酮在常规使用中已变得极为重要。格列美脲刺激β细胞分泌并导致血糖值降低，而罗格列酮激活过氧化物酶体增殖物激活受体γ（PPARγ）并改善血管和代谢活跃细胞处的胰岛素抵抗。因此，两种药物联合使用可能是改善血糖控制和降低心血管风险的一种有趣方法。两种药物的固定复方制剂已在美国和欧盟获批用于临床。格列美脲和罗格列酮的联合用药一般耐受性良好，使用固定复方制剂可能会提高患者对治疗的依从性。本综述的目的是评估已发表的关于这种联合用药的临床数据，这似乎是在2型糖尿病患者中实现治疗目标的一种便捷方法。
